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A B S T R A C T
Purpose
Few patients 75 years of age and older participate in clinical trials, thus whether adjuvant
chemotherapy for stage III colon cancer (CC) benefits this group is unknown.
Methods
A total of 5,489 patients  75 years of age with resected stage III CC, diagnosed between 2004
and 2007, were selected from four data sets containing demographic, stage, treatment, and
survival information. These data sets included SEER-Medicare, a linkage between the New York
State Cancer Registry (NYSCR) and its Medicare programs, and prospective cohort studies Cancer
Care Outcomes Research and Surveillance Consortium (CanCORS) and the National Comprehen-
sive Cancer Network. Data sets were analyzed in parallel using covariate adjusted and propensity
score (PS) matched proportional hazards models to evaluate the effect of treatment on survival. PS
trimming was used to mitigate the effects of selection bias.
Results
Use of adjuvant therapy declined with age and comorbidity. Chemotherapy receipt was associated
with a survival benefit of comparable magnitude to clinical trials results (SEER-Medicare PS-
matched mortality, hazard ratio [HR], 0.60; 95% CI, 0.53 to 0.68). The incremental benefit of
oxaliplatin over non–oxaliplatin-containing regimens was also of similar magnitude to clinical trial
results (SEER-Medicare, HR, 0.84; 95% CI, 0.69 to 1.04; NYSCR-Medicare, HR, 0.82, 95% CI, 0.51 to 1.33)
in two of three examined data sources. However, statistical significance was inconsistent. The beneficial
effect of chemotherapy and oxaliplatin did not seem solely attributable to confounding.
Conclusion
The noninvestigational experience suggests patients with stage III CC  75 years of age may
anticipate a survival benefit from adjuvant chemotherapy. Oxaliplatin offers no more than a small
incremental benefit. Use of adjuvant chemotherapy after the age of 75 years merits consideration
in discussions that weigh individual risks and preferences.
J Clin Oncol 30:2624-2634. © 2012 by American Society of Clinical Oncology
INTRODUCTION
Colorectal cancer is a disease of aging. Of the 141,000
people diagnosed with colorectal cancer in the
United States in 2011,1 40% will be 75 years of age or
older.2,3 Patients older than 75 years also account for
half of colorectal cancer deaths.1 Despite this dispro-
portionate burden, older patients are underrepre-
sented in clinical trials of colorectal cancer
chemotherapy. With scarce efficacy data, elderly pa-
tients and their physicians lack clear standards to
guide treatment decisions.
For patients with stage III colon cancer, adju-
vant chemotherapy after curative intent surgical re-
section improves the chance of cure. Adjuvant
treatment options include fluorouracil with mod-
ulating leucovorin (FU), the oral FU prodrug
capecitabine, or the combination of FU or cape-
citabine with oxaliplatin. FU significantly im-
proves disease-free survival (DFS) and overall
survival (OS) over surgery alone, with relative risk re-
ductions of 30% and 26% respectively.4 The MOSAIC
(Multicenter International Study of Oxalipla-
tin/5-Fluorouracil/Leucovorin in the Adjuvant
Treatment of Colon Cancer) trial demonstrated
that the addition of oxaliplatin to this FU back-
bone further improves DFS by 23% and OS by
20%, leading to a 4.2% absolute improvement
JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T
VOLUME 30  NUMBER 21  JULY 20 2012
2624 © 2012 by American Society of Clinical Oncology
in OS for the FU/oxaliplatin-treated patients with stage III
colon cancer.5,6
However, the two major trials demonstrating the efficacy of ad-
juvant oxaliplatin enrolled only 25 ( 1%) and 131 (5%) patients
 75 of age each (D.J. Sargent, personal communication, November
2009).5,7 In light of the small number of older patients in these trials,
investigators have pooled data from multiple trials to increase the
statistical power in the elderly subgroup. An analysis of patients older
than 70 years treated with adjuvant FU found no evidence of dimin-
ishing effect of chemotherapy on cancer recurrences or deaths with
increasing age, but this study predates the oxaliplatin era.8 An analysis
of more contemporary trials found that the incremental benefit of
oxaliplatin was less for patients older than 70 years than for younger
patients.9 Thus the extent to which patients older than 75 years benefit
from postsurgical chemotherapy remains a challenge that is frequently
encountered in oncology practice. To shed light on actual practice
patterns and outcomes, we evaluated the effectiveness of any adjuvant
chemotherapy for patients older than 75 years with stage III colon




Four data sources were assembled: (1) the SEER program cancer registry
linked to Medicare claims (SEER-Medicare), (2) the New York State Cancer
Registry (NYSCR) linked to Medicare claims, (3) the National Comprehensive
Cancer Network (NCCN) Outcomes Database, and (4) the Cancer Care
Outcomes Research & Surveillance Consortium (CanCORS). The National
Cancer Institute’s SEER program collects data on incident cancer diagnoses
from registries covering 26% of the US population. SEER-Medicare links
patients with cancer to their corresponding Medicare claims for investigation
of treatment and outcomes.10,11 The NYSCR-Medicare data allow for similar
investigation of treatment outcomes for patients diagnosed in New York State.
Since 2005, the NCCN Outcomes Database has prospectively abstracted data
on incident colorectal cancers from medical records at eight National Cancer
Institute–designated Comprehensive Cancer Centers.12,13 CanCORS is a
population- and health system–based cohort study of patients diagnosed with
colorectal cancer between 2004 and 2007 from four geographical regions,
five large health maintenance organizations, and 15 Veterans’ Administra-
tion hospitals.14,15 In CanCORS, demographics were collected by patient
survey. Tumor site, stage, and treatment were ascertained through medical
record review.
Case Eligibility
All patients were  75 years of age at time of diagnosis, had histologically
confirmed stage III adenocarcinoma of the colon resected  90 days from
diagnosis, and survived  30 days after surgery (Fig 1). Exclusions were rectal
cancer, prior history of colon cancer, and autopsy diagnoses. Patients in SEER-
Medicare and NYSCR-Medicare were excluded if enrolled in a health mainte-
nance organization or not continuously enrolled in both Medicare Parts A and
B for 6 months from diagnosis to ensure all claims were available for analysis.
Those diagnosed before 2004, the year of oxaliplatin’s approval for this indi-
cation, were excluded.
Ascertainment of Treatment
This investigation included two main treatment comparisons: chemo-
therapy versus no chemotherapy and, for the subset treated with chemother-
apy, oxaliplatin-containing versus non–oxaliplatin-containing treatment
regimens. For the Medicare cohorts, treatment was ascertained based on the
presence of billing codes for chemotherapy, including the presence of specific
J codes for oxaliplatin. Medical records were the source of treatment informa-
tion in NCCN and CanCORS.
The no chemotherapy group included patients with no claim or record
for chemotherapy within 120 days of surgery; those with a claim/record within
120 days of surgery comprised the chemotherapy group. This chemotherapy
group was divided into an oxaliplatin group—any claim/record of oxaliplatin
within 30 days of the first chemotherapy dose—and a nonoxaliplatin group—
patients without oxaliplatin claim/record, including those receiving oral, bo-
lus, and infusional FU.16-19 Because of the small number of oxaliplatin-treated
patients, chemotherapy regimens were not compared in CanCORS.
Statistical Methods
Covariates in effectiveness data sets. Variables common to all four data
sets included age, race, sex, marital status, year of diagnosis, tumor substage,
and tumor grade. Income based on residence zip code or census tract was
available forSEER-Medicare,NCCN,andNYSCR;CanCORScontains individual
estimates. Comorbidity was measured by the Charlson Comorbidity Index in
NCCN, the Deyo modification of the Charlson Comorbidity Index in NYSCR-
Medicare, and the Deyo-Klabunde modification in SEER-Medicare.20-22 Comor-
bidity in CanCORS was measured using the Adult Comorbidity Evaluation–27
index.13,23 Given the presumed key contribution of comorbid conditions to
treatment and outcomes in older patients, though measured differently in each
sample, comorbidity was retained in all analyses.
OS. The primary outcome of interest was OS, measured from 30 days
after surgery until death from any cause. This was chosen as the anchor date
because it could be reliably ascertained and consistently measured for all
cohorts. Because the survival measure began 90 days before the chemotherapy
exposure window ended, we explored the potential for immortal person-time
bias whereby patients dying during the exposure window have a lower chance
of receiving treatment, thus worsening the outcome of the no treatment
group.24 In the no chemotherapy group, 12% of patients in SEER-Medicare
and 13% in NYSCR died within 120 days of surgery compared with only 3% of
patients in the chemotherapy group. Thus patients dying within 120 days of
surgery were excluded from the survival comparison of chemotherapy versus
no chemotherapy to minimize bias. Sensitivity analysis showed that anchoring
survival at 120 days instead of 30 days had little effect on outcomes, thus 30
days was retained to better approximate clinical trials survival estimates.
Analysis. Because of the heterogeneous methods of data ascertainment
and measurement across cohorts as well as stipulations in data use agreements,
data sets were not combined. Instead, we applied consistent inclusion criteria
and covariate specifications across cohorts in parallel. Within each cohort,
univariate and multivariate logistic regressions assessed associations between
covariates, chemotherapy use, and oxaliplatin receipt. OS of treatment groups
were compared descriptively by Kaplan-Meier survival estimates.
Because treatment effect estimates are likely confounded by factors re-
lated to treatment selection, we performed a propensity score (PS) matched
analysis to compare the effect of treatment on survival among patients of
similar risk profiles as assessed by measured, known confounders.25,26 To do
so, we generated two PSs: one estimated the likelihood of chemotherapy
receipt, and the other estimated the likelihood of oxaliplatin receipt in chem-
otherapy-treated patients. For each comparison, exposed patients (eg, chem-
otherapy, oxaliplatin) were matched to patients with the same PS from the
unexposed treatment group. Patients for whom there was no match were
excluded. In this way, we generated a PS-matched cohort balanced across
treatment groups for measured confounders. OS survival was then compared
in these PS-matched cohorts. PS matching was not performed with NCCN
because of small sample and data use agreements. Instead, a Cox proportional
hazards model adjusted for confounding.
To estimate the extent to which unmeasured confounding was respon-
sible for the measured treatment effect, we conducted a sensitivity analysis
whereby patients treated contrary to their PS prediction were trimmed from
the sample.27 Because patients treated contrary to prediction are most likely to
have unmeasured confounders determining their treatment selection (eg,
frailty), omitting them increases the validity of the treatment effect estimate.27
If the observed treatment effect estimate is largely due to unmeasured con-
founding, with trimming the survival hazard ratio (HR) should more closely
approach the null. Trimming was conducted in an asymmetric iterative fash-
ion by percentiles at cut points of 1%/99%, 2.5%/97.5%, and 5%/95%.27 After
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each iteration, PS matching was again performed and a survival HR calculated
for the trimmed, matched group.
RESULTS
A total of 5,489 patients  75 years of age with resected stage III colon
cancer were included: 4,226 from SEER-Medicare, 998 from the
NYSCR-Medicare, 121 from CanCORS, and 144 from NCCN (Table
1). Because of differences in cohort assembly, there were substantial
differences in the distribution of important covariates, such as sex,
race, and income, across cohorts.
Three hundred sixty-four (9%) patients in SEER-Medicare and 78
patients (8%) in NYSCR-Medicare died within 120 days of colon resec-
tion.Thesepatientswhodiedwithin120daysofsurgeryweresubstantially
older than the surviving patients. Only 50 patients in SEER-Medicare and
13 patients in NYSCR-Medicare received any chemotherapy before
dying 120 days after surgery, which is 3% of chemotherapy-treated
patients in each cohort. Only one NCCN and no CanCORS chemo-
therapy-treated patients died within 120 days of surgery.
The use of any chemotherapy after resection of stage III cancer
differed across cohorts: 42% in SEER-Medicare, 45% in NYSCR-
Medicare,52%inCanCORS,and75%inNCCN.Amongthosereceiving
recnac noloc III egatS  
 SEER NYSCR CanCORS NCCN
 (N = 14,706) (N = 4,843) (N = 523) (N = 900)
sisongaid ta evilA 
 SEER NYSCR CanCORS NCCN
 (n = 14,689) (n =  4,842) (n = 523) (n = 900)
recnac noloc suoiverp oN 
 SEER NYSCR CanCORS NCCN
 (n = 13,587) (n =  4,065) (n = 523) (n = 889)
redlo ro sraey 57 egA  
 SEER NYSCR CanCORS NCCN
 (n = 6,522) (n = 1,543) (n = 150) (n = 157)
 noitceseR ≤ 90 days after diagnosis
 SEER-Medicare* NYSCR-Medicare† CanCORS NCCN
 (n = 5,230) (n = 1,414) (n = 128) (n = 151)
 Continuous Medicare A&B enrollment for 6 months after diagnosis
 SEER-Medicare NYSCR-Medicare CanCORS NCCN
 (n = 5,066) (n = 1,380) NA NA
 Not enrolled in Medicare managed care/HMO for 6 months after diagnosis
 SEER-Medicare NYSCR-Medicare CanCORS NCCN
 (n = 4,564) (n = 1,096) NA NA
yregrus retfa syad 03 devivruS 
 SEER-Medicare NYSCR-Medicare CanCORS NCCN
 (n = 4,226) (n =  998) (n = 121) (n = 146)




 Medicare Medicare CanCORS NCCN
 (n = 2,453) (n = 549) (n = 58) (n = 36)
 Chemotherapy
 SEER- NYSCR-
 Medicare Medicare CanCORS NCCN
 (n = 1,773) (n = 449) (n = 63) (n = 110)
 Survived 120 days after surgery:
 analytic treatment group, no chemotherapy
 SEER- NYSCR-
 Medicare Medicare CanCORS NCCN
 (n = 2,139) (n = 484) (n = 58) (n = 35)
 Survived 120 days after surgery:
 analytic treatment group, chemotherapy
 SEER- NYSCR-
 Medicare Medicare CanCORS NCCN
 (n = 1,723) (n = 436) (n = 63) (n = 109)
Oxaliplatin in first 30
days of chemotherapy YesNo
 Analytic treatment group, no oxaliplatin
 SEER- NYSCR-
 Medicare Medicare NCCN
 (n = 1,163) (n = 325) (n = 42)
 Analytic treatment group, oxaliplatin‡
 SEER- NYSCR-
 Medicare Medicare NCCN
 (n = 610) (n = 124) (n = 66)
Fig 1. Cohort assembly CONSORT dia-
gram. (*) SEER cases and Medicare
claims were linked at this step. (†) New
York State Cancer Registry (NYSCR)
cases and Medicare claims were linked at
this step. (‡) Cancer Care Outcomes Re-
search and Surveillance Consortium (Can-
CORS) cases were not included in the
oxaliplatin versus nonoxaliplatin compari-
son because of small numbers of
oxaliplatin-treated patients. In National
Comprehensive Cancer Network (NCCN),
two patients were dropped because the
chemotherapy regimen could not be de-
termined. NA, not applicable.
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Table 1. Characteristics of Elderly Patients With Resected Stage III Colon Cancer
Characteristic
SEER-Medicare (n  4,226) NYSCR-Medicare (n  998)
CanCORS (n  121) NCCN (n  144)
No chemo
(n  2,453)
Chemo (n  1,773; 42%)
No Chemo
(n  549)








(n  36; 25%)













(n  42; 39%)
Oxaliplatin
(n  66; 61%)
No. % No. % No. % No. % No. % No. % No. % No. % No. % No. % No. %
Age, years b
Median 84 80 78 83 80 78 79 80 78
Range 75-105 75-95 75-89 75-101 75-94 75-90 75-92 75-88 75-109
75-79 565 23 530 46 445 73 93 17 120 37 68 55 c 31 49 18 50 18 43 51 77
80-84 (CanCORS 80-81) 823 34 466 40 152 25 190 35 140 43 41 33 23 40 13 21 18 50 24 57 15 23
85 (CanCORS  82) 1,065 43 167 14 13 2 266 48 65 20 15 12 35 60 19 30 c c c
Sex
Female 1,631 66 693 60 330 54 361 66 190 58 67 54 31 53 28 44 22 61 16 38 35 53
Male 822 34 470 40 280 46 188 34 135 42 57 46 27 47 35 56 14 39 26 62 31 47
Race
White 2,081 85 979 84 524 86 494 90 287 88 117 94 43 74 46 73 30 83 34 81 58 88
Black 211 9 64 6 39 6 42 8 20 6 d d d d d d
Asian 87 4 62 5 27 4 13 2 18 6 d d d d d d
Other 74 3 58 5 20 3 c c 0 0 d d d d d
Latino
Yes 111 5 70 6 35 6 32 6 17 5 d e — d d d
No 2,342 95 1,093 94 575 94 517 94 308 95  90f — — 32 89 37 88 58 88
Unknown d d d
Charlsong
0 1,196 49 650 56 381 62 349 64 229 70 93 75 NA NA 17 47 18 43 34 52
1 670 27 319 27 159 26 103 19 54 17 31 25 19 53 24 57 31 48
 2 587 24 194 17 70 11 97 18 13 42 c c c c
ACE-27
None NA NA NA NA NA NA c c NA NA NA
Mild 34 59 41 65
Moderate 24 41 22 35
Severe c c
Marital status
Married 865 35 591 51 351 58 154 28 146 45 54 44 24 41 35 56 NA NA NA
Single 191 8 65 6 33 5 77 14 46 14 16 13 e e
Widow/divorce 1,302 53 471 40 196 36 318 58 133 41 54 44 33 56 28 44
Other 95 4 36 3 30 5 c c c c c
AJCC stage
IIIa 232 9 119 10 47 8 56 10 40 12 c c 13 21 d c d
IIIb 1,499 61 672 58 314 51 326 59 176 54 76 61 43 74 31 49 26 72 27 65 39 59
IIIc 722 29 372 32 249 41 167 30 109 34 48 39 15 26 19 30 d 15 35 17 26
IIINOS c c 0 0 c c 0 0 0 0 d
Tumor grade
Well differentiated 121 5 51 4 40 7 357 65 189 58 68 55 d d 0 0 d c
Moderately
differentiated 1,491 61 690 59 357 59 192 35 121 37 55 45 38 66 46 73 21 58 32 76 40 61
Un/poorly differentiated 790 32 399 34 199 33 c 15 5 c 16 28 d 15 42 c 26 39
Unknown 51 2 23 2 14 2 d d c 0 0 0 0
Median income
Top quantile 200,008 159,521 151,970 134,325 131,402 200,000 h — 87,638 99,076 111,492
3rd quantile 45,665 46,214 51,199 58,803 62,569 63,379 — — 54,677 64,787 67,226
2nd quantile 35,064 35,317 38,478 43,035 46,291 51,565 — — 41,455 47,456 48,744
1st quantile 27,195 27,526 28,892 33,990 33,573 35,425 — — 33,656 37,996 38,487
Bottom quantile 7,344 8,544 10,076 14,896 14,271 20,582 — — 17,529 18,968 20,334
Missing
Year of diagnosis
2004 624 25 390 34 82 13 190 35 144 44 28 23 58 100 51 81 — — —
2005 647 26 336 29 165 27 189 34 101 31 38 31 c 12 19 16 (2005-2006) 45 16 (2005-2006) 38 24 (2005-2006) 37
2006 591 24 208 18 167 27 170 31 80 25 58 47 — — c c c
2007 591 24 229 20 196 32 — — — — — 20 (2007-2009) 55 26 (2007-2009) 62 15 23
2008 — — — — — — — — c c 27 (2008-2009) 40
2009 — — — — — — — — c c c
Time from surgery to first
chemo, days NA NA NA NA
Median 47 47 48 46 43 51 51
Range 0-119 10-120 5-120 17-115 20-116 25-116 22-117
(continued on following page)
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chemotherapy, a smaller proportion of patients received oxaliplatin as a
component of their adjuvant therapy in SEER-Medicare (42%), and
NYSCR-Medicare (28%), than at NCCN centers (61%). As expected,
the use of both any chemotherapy and oxaliplatin-containing regi-
mens dropped off quickly with advancing age. In multivariate models,
age was the factor most strongly associated with both chemotherapy
and oxaliplatin receipt (Fig 2; Appendix Tables A3 and A4, online
only). Compared with 63% of patients 75 to 79 years of age, only 43%
of patients 80 to 84 years of age (odds ratio [OR], 0.44; 95% CI, 0.38 to
0.51) and 14% of patients 85 years of age and older (OR, 0.10; 95% CI,
0.08to0.12)inSEER-Medicarereceivedpostoperativeadjuvantchem-
otherapy. Of patients treated with chemotherapy, 46% of patients 75
to 79 years of age compared with 25% of patients 80 to 84 years of age
(OR, 0.37; 95% CI, 0.29 to 0.46) and 7% of patients 85 years of age and
older (OR, 0.08; 95% CI, 0.05 to 0.15) in SEER-Medicare received
oxaliplatin. Black elderly patients seemed to be less likely to receive
chemotherapy, and Asian patients seemed to be more likely to receive
chemotherapy. Small sample sizes, however, limit interpretation
about care patterns in these subgroups.
Survival of chemotherapy-treated patients was substantially bet-
ter than survival of patients not receiving chemotherapy after resec-
tion of stage III colon cancer (Table 2; Fig 3). Chemotherapy use was
Table 1. Characteristics of Elderly Patients With Resected Stage III Colon Cancer (continued)
Characteristic
SEER-Medicare (n  4,226) NYSCR-Medicare (n  998)
CanCORS (n  121) NCCN (n  144)
No chemo
(n  2,453)
Chemo (n  1,773; 42%)
No Chemo
(n  549)








(n  36; 25%)













(n  42; 39%)
Oxaliplatin
(n  66; 61%)
No. % No. % No. % No. % No. % No. % No. % No. % No. % No. % No. %
F/U time, days
Median 740 1,109 1,053 552 772 601 1,260 1,260 780 984 823
Range 0-2,153 17-2,154 29-2,133 0-1,422 30-1,430 39-1,397 131-1,260 147-1,260 38-1,930 275-1,874 100-1,872
Abbreviations: ACE-27, Adult Comorbidity Evaluation–27; AJCC, American Joint Committee on Cancer; CanCORS, Cancer Care Outcomes Research and
Surveillance Consortium; CCI, Charlson Comorbidity Index; Chemo, chemotherapy; F/U, follow-up; FU, fluorouracil with modulating leucovorin; NA, not applicable;
NCCN, National Comprehensive Cancer Network; NOS, not otherwise specified; NYSCR, New York State Cancer Registry.
aOnly 10 patients in CanCORS received oxaliplatin; therefore, the chemo group is not subdivided to preserve patient confidentiality and because of the limitation
of analysis of such a small sample.
bAge was measured categorically in CanCORS, median is not available. Catergories are 75-79, 80-81,  82.
cCollapsed with category above/below because of small numbers to preserve confidentiality.
dEleven or fewer patients; number omitted to preserve confidentiality.
eLatino patients in CanCORS are combined with “Other” because of small numbers. Single patients were combined with “Other” because of small numbers.
fThe majority of oxaliplatin-treated patients in NYSCR-Medicare were non-Latino. The exact number is masked to preserve confidentiality of the Latino patients.
gComorbidity is measured with the CCI in NCCN, the Deyo-Klabunde modification in SEER-Medicare, and the Deyo modification in NYSCR-Medicare. Comorbidity
is measured by the ACE-27 in CanCORS.






































































































































Fig 2. Percentage of elderly patients with stage III colon cancer treated with chemotherapy. The percentage of patients treated with chemotherapy (A) or oxaliplatin
(B) is shown broken down by strata of clinically relevant covariates. Bars representing 11 or fewer patients were omitted to preserve patient confidentiality. Comorbidity
is measured with the Charlson Comorbidity Index in National Comprehensive Cancer Network (NCCN), the Deyo-Klabunde modification in SEER-Medicare, the Deyo
modification in New York State Cancer Registry (NYSCR) –Medicare, and the Adult Comorbidity Evaluation–27 in Cancer Care Outcomes Research and Surveillance
Consortium (CanCORS).
Sanoff et al
2628 © 2012 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
associated with significantly lower mortality in the PS-matched SEER-
Medicare cohort (HR, 0.60; 95% CI, 0.53 to 0.68), with a comparable
effect in the PS-matched NYSCR-Medicare (HR, 0.76; 95% CI, 0.58 to
1.01) and CanCORS (HR, 0.48; 95% CI, 0.19 to 1.21) cohorts. The
Cox proportional hazards–adjusted NCCN analysis also showed a
reduction in mortality in chemotherapy-treated patients (HR, 0.42;
95% CI, 0.17 to 1.03). Sensitivity analysis showed no evidence of
decreasing treatment effect with PS trimming, suggesting that the
observed reduction in mortality stemmed from treatment and not
simply from unmeasured confounding.27
Oxaliplatin use was associated with a trend toward lower mortal-
ity among chemotherapy-treated elderly patients in SEER-Medicare
(PS-matched HR, 0.84; 95% CI, 0.69 to 01.04) and in NYSCR-
Medicare (PS-matched HR, 0.82; 95% CI, 0.51 to 1.33), both corre-
sponding to a 5% absolute improvement in survival at 3 years in the
PS-matched cohorts (Table 3; Fig 4). In sensitivity analysis, the effect
of oxaliplatin was slightly attenuated by PS trimming in SEER-
Medicare with a trimmed HR of 0.87 compared with 0.84, and in
NYSCR with a trimmed HR of 0.88 compared with 0.82. Among the
108 chemotherapy-treated patients with age  75 years in NCCN,
there was no apparent benefit associated with oxaliplatin receipt, with
exceptionally high 3-year survival of 88% in non–oxaliplatin-treated
and 84% in oxaliplatin-treated patients.
DISCUSSION
People  75 years of age comprise 40% of the colorectal cancer
population.3 Although oxaliplatin increases cure rates for resectable
stage III cancer in clinical trials, only 5% of patients enrolled to Na-
tional Surgical Adjuvant Breast and Bowel Project Trial C07 and fewer
than 1% of MOSAIC participants were 75 years of age or older, so the
benefit demonstrated by those trials has not been established in the
older population. Perhaps as a result of the lack of data in elderly
patients, chemotherapy use decreases rapidly with age.15,28 Facing this
gap in the clinical trials evidence, we sought to examine the use and
comparative effectiveness of adjuvant chemotherapy, and more spe-
cifically adjuvant oxaliplatin, in patients 75 years of age and older with
stage III colon cancer.
We found that among patients 75 years of age and older surviving
120 days from resection, those treated with adjuvant chemotherapy
had a markedly lower risk of death than those who did not. Using
effectiveness cohorts reflecting heterogeneous patient populations,
the survival advantage associated with adjuvant chemotherapy was
comparable to that demonstrated in clinical trials. In fact, the survival
advantage was more substantial than has previously been measured in
pooled trials data, where adjuvant FU resulted in a 24% reduction in
the risk of death.8 Two SEER-Medicare analyses of patients treated for
stage III colon cancer in the mid-1990s suggested similar treatment
effect sizes (27% and 35% relative risk reductions).29,30 That we found
greater association between adjuvant treatment and survival with the
inclusion of more recent data may be attributable to the fact that 34%
of patients received oxaliplatin. In sensitivity analysis, excluding
oxaliplatin-treated patients decreased 3-year survival from 70% to
67% in SEER-Medicare, although this had little effect on the survival
HR. If over time, given the emphasis on adjuvant treatment for stage
III colon cancer as a quality metric, clinicians have become more
comfortable treating older patients with adjuvant therapy, we would
anticipate that patients in the no chemotherapy group would become
Table 2. Benefit of Adjuvant Chemotherapy Among Elderly Patients With Stage III Colon Cancer
Patient Group and Survival
Chemotherapy v No Chemotherapy









Entire cohort 2,453 1,773 549 449 58 63 36 110
Restricted to patients surviving
120 days from surgery 2,139 1,723 484 436 58 (100%) 63 (100%) 35 (97%) 109 (99%)
PS-matched cohort 1,174 1,174 277 277 33 33 NA NA
3-year OS, unmatched cohort
(120-day survivors only), % 50 70 53 63 60 78 59 87
3-year OS, PS-matched cohort
(120-day survivors only), % 53 68 53 60 50 71 NA NA
Crude mortality unmatched
HR 1 0.51 1 0.72 1 0.49 1 0.35
95% CI 0.46 to 0.56 0.58 to 0.90 0.25 to 0.95 0.16 to 0.77
PS matched mortality 
HR 1 0.60 1 0.76 1 0.48 1 0.42
95% CI 0.53 to 0.68 0.58 to 1.01 0.19 to 1.21 0.17 to 1.03
Trimmed, PS matched mortality NA NA
HR 1 0.62 1 0.72 1 0.31
95% CI 0.54 to 0.71 0.53 to 0.97 0.10 to 0.96
NOTE. Three-year OS and HR with 95% CI from an unadjusted Cox proportional hazards model and a PS-matched and trimmed analysis are shown according to
the type of postoperative therapy delivered in patients surviving 120 days from surgical resection.
Abbreviations: CanCORS, Cancer Care Outcomes Research and Surveillance Consortium; HR, hazard ratio; NA, not applicable; NCCN, National Comprehensive
Cancer Network; NYSCR, New York State Cancer Registry; OS, overall survival; PS, propensity score.
The PS analysis could not be performed in NCCN because of small sample size and data use agreements. An adjusted Cox proportional HR is shown for NCCN
including age, sex, ethnicity, race, comorbidity, tumor substage, tumor grade, and income.
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No. at risk
Chemotherapy 436 415 367 296 220 166 111
No chemotherapy 484 433 382 278 210 135 93
No chemotherapy, unmatched (n = 484); 
3-year survival, 53%
Chemotherapy, unmatched (n = 436); 
3-year survival, 63%























6 12 18 24 30 36
No. at risk
Chemotherapy 277 268 236 186 132 93 69
No chemotherapy 277 251 218 155 111 77 52 
No chemotherapy, matched (n = 277); 
3-year survival, 53%
Chemotherapy, matched (n = 277); 
3-year survival, 60%






















6 12 18 24 30 36
No. at risk
Chemotherapy 1,723 1,668 1,553 1,444 1,326 1,090 875
No chemotherapy 2,139 1,978 1,691 1,456 1,249 1,001 743
No chemotherapy, unmatched (n = 2,453); 
3-year survival, 50%
Chemotherapy, unmatched (n = 1,773); 
3-year survival, 70%























6 12 18 24 30 36
No. at risk
Chemotherapy 1,174 1,132 1,051 978 893 723 588
No chemotherapy 1,174 1,085 942 828 710 573 442
No chemotherapy, matched (n = 1,174); 
3-year survival, 53%
Chemotherapy, matched (n = 1,174); 
3-year survival, 68%






















6 12 18 24 30 36
No. at risk
Chemotherapy 63 62 59 57 55 51 49
No chemotherapy 58 56 50 43 40 38 35
No chemotherapy, unmatched (n = 58); 
3-year survival, 60%
Chemotherapy, unmatched (n = 63); 
3-year survival, 78%























6 12 18 24 30 36
No. at risk
Chemotherapy 109  97  65  42
No chemotherapy 35  26  19  10
No chemotherapy, unmatched (n = 35); 
3-year survival, 59%
Chemotherapy, unmatched (n = 109); 
3-year survival, 87%
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Fig 3. Unadjusted and propensity score–matched Kaplan-Meier survival comparisons of chemotherapy versus no chemotherapy in elderly patients with stage III colon
cancer surviving 120 days from surgery. (A) SEER-Medicare unmatched; (B) SEER-Medicare matched; (C) New York State Cancer Registry (NYSCR) –Medicare
unmatched; (D) NYSCR-Medicare matched; (E) Cancer Care Outcomes Research and Surveillance Consortium unmatched; (F) National Comprehensive Cancer Network
unmatched. HR, hazard ratio.
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more frail over time. The association between adjuvant treatment and
survival could be increasing if such selection bias is operational. This
bias likely underlies the large effect of chemotherapy measured in
NCCN, where patients were more the most likely to get both chemo-
therapy and oxaliplatin. Although we used available methods to mit-
igate such selection, including PS-trimmed sensitivity analysis,27 no
method can overcome all such bias in observational data.
The incremental decrease in mortality seen with the addition of
oxaliplatin in elderly patients in the community was of comparable
size as seen in the MOSAIC and the XELOX in Adjuvant Colon Cancer
Treatment (XELOXA) trials, which reported 20% and 13% relative
mortality reductions from oxaliplatin, respectively.6,31 In our effec-
tiveness cohorts, relatively small sample sizes limited our ability to
evaluate the association between oxaliplatin-containing adjuvant
therapy and survival. With the oxaliplatin results considered in paral-
lel, the consistency of the point estimates in the two Medicare cohorts
is reassuring. However, with the modest attenuation of oxaliplatin
effect in the PS-trimmed sensitivity analysis and the lack of benefit at
the NCCN centers, the incremental survival associated with oxalipla-
tin in this oldest group of treated colon cancer patients seems to be
very modest.
Reports of the effect of FU/oxaliplatin combination chemother-
apy in patients older than 70 years in clinical trials do not clearly
support its benefit over FU. In an analysis of infusional fluorouracil,
leucovorin, and oxaliplatin using pooled data from three trials of
metastatic colon cancer and one adjuvant trial (MOSIAC), improve-
ments in progression-free survival, disease-free survival (DFS), and
OS were similar among older patients compared with younger ones.32
However, the subgroup analysis of patients  65 years of age in
MOSAIC found no survival benefit from oxaliplatin.6 In the XELOXA
trial, oxaliplatin’s effect on DFS in patients older than 70 years was less
robust than in younger patients: DFS HR in patients younger than 70
years, 0.79; 95% CI, 0.66 to 0.94; DFS HR in patients  age 70 years,
0.87; 95% CI, 0.63 to 1.18.33 No DFS or OS benefit was gained in
National Surgical Adjuvant Breast and Bowel Project Trial C07 by
adding oxaliplatin in patients older than 70 years.34 In addition, in a
recent analysis of trials in which novel adjuvant chemotherapies
(capecitabine, FU/irinotecan, and FU/oxaliplatin) were compared
with an FU control, patients older than 70 years did not benefit from
any newer regimen, even when younger patients did. In the case of
oxaliplatin-based therapies, there was no survival benefit from oxalip-
latin in patients older than 70 years (OS HR, 1.13; 95% CI, 0.96 to 1.32;
DFS HR, 1.11; 95% CI, 0.97 to 1.28).9
It seems implausible that oxaliplatin is truly more effective in
patients older than 75 years in the community than in patients older
than 70 years in randomized trials. Therefore, although the general
consistency of findings, including the PS-trimmed models, strength-
ens our confidence that both chemotherapy in general and oxaliplatin
in particular improves outcomes of elderly patients with colon cancer,
it seems likely that despite attempts to control for unmeasured con-
founding, the inherent differences between FU and oxaliplatin pa-
tients were not fully accounted for in our analyses. Ideally, clinical
trials would recruit subjects whose characteristics mirror those of the
affected population thereby strengthening our certainty with regard to
the utility of oxaliplatin in the oldest patients with colon cancer.
However, given that drug development studies must ask “How well
can this treatment work?” trial populations will likely continue to
under-represent the elderly. As such, efforts to examine effectiveness
by leveraging best available data sources and most careful analytic
techniques remain a priority.
This study suggests that patients older than 75 years of age with
surgically resected colon cancer may experience a survival benefit
from chemotherapy comparable to that previously demonstrated by
younger populations in randomized and observational studies.4-6,35
From the perspective of a practicing clinician, these results suggest that
consideration of adjuvant systemic therapy is absolutely warranted for
Table 3. Benefit of Adjuvant Oxaliplatin Among Elderly Patients With Stage III Colon Cancer
Patient Group and Survival














PS matched 512 512 110 110 NA NA
3-year OS, unmatched cohort, % 65 74 59 66 88 84
3-year OS, PS-matched cohort, % 68 73 61 66 NA NA
Crude mortality unmatched
HR 1 0.71 1 0.83 1 1.25
95% CI 0.60 to 0.85 0.56 to 1.22 0.43 to 3.68
PS matched mortality 
HR 1 0.84 1 0.82 1 1.84
95% CI 0.69 to 1.04 0.51 to 1.33 0.48 to 7.05
Trimmed, PS matched mortality NA NA
HR 1 0.87 1 0.88
95% CI 0.69 to 1.10 0.51 to 1.53
NOTE. Three-year OS and HR with 95% CI from an unadjusted Cox proportional hazards model and a PS-matched and trimmed analysis are shown according to
the type of postoperative chemotherapy delivered.
Abbreviations: HR, hazard ratio; NA, not applicable; NCCN, National Comprehensive Cancer Network; NYSCR, New York State Cancer Registry; OS, overall survival;
PS, propensity score.
The PS analysis could not be performed in NCCN because of small sample size and data use agreements. An adjusted Cox proportional HR is shown for NCCN
including age, sex, ethnicity, race, comorbidity, tumor substage, tumor grade, and income.
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patients older than 75 years. Because quality of life could not be
measured in this analysis, how adjuvant therapy affects the quality of
life of older patients with cancer remains a critical, unanswered ques-
tion. Clearly, treatment decisions need to be made in the context of
individual risk profiles and preferences, but the survival estimates
from this work provide benchmarks for consideration and may in-
form discussions about prognosis. Future research examining addi-
tional or larger cohorts may further qualify this study’s findings, for
No. at risk
Oxaliplatin 124 118 102 80 54 37 28
Nonoxaliplatin 325 297 265 221 169 129 92
Nonoxaliplatin, unmatched (n = 325); 
3-year survival, 59%
Oxaliplatin, unmatched (n = 124); 
3-year survival, 66%























6 12 18 24 30 36
No. at risk
Oxaliplatin 110 105 91 74 53 36 27
Nonoxaliplatin 110 103 92 70 46 41 41
Nonoxaliplatin, matched (n = 110); 
3-year survival, 61%
Oxaliplatin, matched (n = 110); 
3-year survival, 66%






















6 12 18 24 30 36
No. at risk
Oxaliplatin 610 590 555 528 483 383 288
Nonoxaliplatin 1,163 1,078 998 916 843 707 587
Nonoxaliplatin, unmatched (n = 1,163);
3-year survival, 65%
Oxaliplatin, unmatched (n = 610); 
3-year survival, 74%























6 12 18 24 30 36
No. at risk
Oxaliplatin 512 494 462 439 404 323 252
Nonoxaliplatin 512 478 445 418 382 305 238
Nonoxaliplatin, matched (n = 512); 
3-year survival, 68%
Oxaliplatin, matched (n = 512); 
3-year survival, 73%






















6 12 18 24 30 36
No. at risk
Oxaliplatin 66  57  38  26
Nonoxaliplatin 42  38  25  14
Nonoxaliplatin, unmatched (n = 42); 
3-year survival, 88%
Oxaliplatin, unmatched (n = 66); 
3-year survival, 84%
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Fig 4. Unadjusted and propensity score–matched Kaplan-Meier survival comparison of oxaliplatin and nonoxaliplatin adjuvant chemotherapy in elderly patients with
stage III colon cancer. (A) SEER-Medicare unmatched; (B) SEER-Medicare matched; (C) New York State Cancer Registry (NYSCR) –Medicare unmatched; (D)
NYSCR-Medicare matched; (E) National Comprehensive Cancer Network unmatched. HR, hazard ratio.
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example, as they may be modulated by specific patient comorbidities,
or as they pertain to a decision to use oxaliplatin versus alternative
systemic therapy. In the meantime, this study helps fill the knowledge
gap left by clinical trials and inform a prevailing bias away from
adjuvant therapy among the oldest patients with colon cancer. The
relative consistency of study findings suggests that patients of this age
group and their physicians should consider adjuvant chemotherapy as
a viable treatment option.
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